• English
    • German

Study – UKE

Study – UKE

The first study with UKE was successfully completed in 2022. The results are outstanding and exceed by far existing diagnostic gold standards for type 2 diabetes. Regarding NAFLD/NASH, they enable completely new approaches to diagnostics.

The head of the study, Professor Dr. Oliver Mann, summarized the results in a letter and outlined further research planning with the Lipocyte BioMed. (Note: At the date of writing, Lipocyte BioMed GmbH was still operating under the name Lipozyt Marker GmbH.)

In particular, it shows that multidimensional analyses are possible through the use of an mRNA panel, which would not be possible if only a single marker were used. Furthermore, looking at the relations between the markers (patterns) allows much more precise and detailed analyses as would be possible, if only threshold values, as in standard diagnostics, were examined. This advantage is reflected in the extremely high “accuracy” of the results (i.e., the product of sensitivity and specificity) of 95% and more.

The results of the study are to be published as soon as possible.

We unlock the treasure trove of the adipose tissue

Subcutaneous adipose tissue (SAT)

The subcutaneous adipose tissue (SAT) plays an important role in the genesis and modulation of metabolic diseases. It offers new opportunities for personalised medicine.

Read more

mRNAs are a key to personalised medicine

mRNAs (messenger RNAs)

mRNAs (messenger RNAs) convey genetic information in the body. They are highly involved in modulating metabolic processes, especially processes of the energy metabolism. Wit metabolic diseases they can be seen as drivers of pathology.

mRNAs – The drivers of pathology

Breaking new ground for
diagnostics, therapeutics and prevention


mRNA-analysis of the SAT offers deep and completely new insights into the energy metabolism. Especially with metabolic diseases the current dynamics of the body and influences over life-time play a far greater role than genetic dispositions

Read more


The key to successful treatment of metabolic diseases lies in the intervention with disease-causing on-going biological processes. As the mRNA of the SAT are to a great extent the drivers of pathology of these diseases, they offer a strong lever for therapy.

Read more


A great advantage of mRNA-analysis of the subcutaneous adipose tissue lies in the very early detection of unhealthy developments of the metabolism long before any signs can be seen in blood-analysis or any symptoms become apparent. It is, therefore, a powerful component in preventive personalised medicine.

Read more